Shot medicine (dupilumab) for severe, unexplained chronic itching
Treatments studied
Part of Skin clinical trials.
This Phase 3 study tests whether dupilumab injections can reduce severe itching that has no clear cause. It also checks how safe the medicine is over the study period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (age 18 to 90) and can sign consent.
- Your itching has lasted at least 6 months and has no clear cause found by the study doctor.
- Your itching affects at least two areas: legs, arms, or your trunk (torso).
- Your itching is very severe: your worst itch is 7 or higher (out of 10) and you rate your itch as “severe.”
- You’ve already tried other treatments but they didn’t control your itching well.
- You are not currently on dupilumab (study drug or commercial), and you don’t have conditions that block safe use (like serious infections, HIV, or certain cancer histories).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a light-based therapy (called photobiomodulation) to see if it can reduce itch. The treatment uses a special light on the skin, which may help calm the nerves or cells that cause itching. You'll have one side of your body treated and the other side not, so the researchers can compare the effects.
This study continues to test an experimental medicine (linerixibat) for itching caused by primary biliary cholangitis (PBC). It's for people who have already been in a prior study of this medicine and may help keep itching under control.
This study tests whether the medication dupilumab can safely reduce itching and skin bumps in children aged 6 months to under 18 years who have prurigo nodularis, a skin condition that causes intense itching and nodules. Participation involves taking the study drug and tracking itch daily.
This trial tests if dupilumab (Dupixent) can help adults with long-lasting, severe itching from healed burn scars. It is for people whose itching has not improved with standard treatments like antihistamines.
This early trial tests whether dupilumab can reduce itching in people with certain inherited (genetic) inflammatory skin conditions. It may help by calming skin inflammation that causes ongoing itch and sleep problems.
This study tests an investigational medicine (remibrutinib) for people with severe itching that has no known cause. It may help reduce the itch when moisturizers haven't worked.
Hear when a new Pruritus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.